Navigation Links
Benaroya Research Institute evaluates immunology approach to blocking breast cancer
Date:4/18/2014

(Seattle, WA April 18, 2014) Benaroya Research Institute at Virginia Mason (BRI) recently received a grant to research how blocking a particular molecule in metastatic breast cancer reduces both the growth of primary tumors and the number of lung metastases. BRI scientists have found in models of the disease that blocking this protein can shrink tumors by 60 - 80 percent and can keep the tumor from metastasizing or spreading to the lung. The $1.8 million five-year grant comes from the National Cancer Institute of the National Institutes of Health.

"We are excited to pursue this area of cancer research that links tumor growth to the type of immune system molecules that my laboratory has focused on for many years," said the Principal Investigator of the grant, Steven F. Ziegler, PhD, Director of the Immunology Program at BRI. "We are looking at ways to block this protein in model systems that could be translated to humans. The goal of this work is to help develop a therapy to reduce primary breast cancer tumors, as well as the spread of this cancer to other areas. We also plan to study this in pancreatic and lung cancer as well because this protein plays a role in these diseases."

In a study of the protein, Thymic Stromal Lymphopoietin (TSLP), in allergic responses Dr. Ziegler and his team used lung cancer as a "negative control group" and surprisingly found very high levels of the protein in people with lung tumors. In 2005, Dr. Ziegler and his colleagues discovered that TSLP was instrumental in initiating the inflammatory cascade that leads to the development of asthma and other allergic diseases. Since then, the researchers also found TSLP to be critical in other immune system diseases. Dr. Ziegler has studied TSLP since l993 and has developed many tools and strategies for studying the protein.

BRI researchers will test several ways to block TSLP to evaluate potential for treatments to help eliminate the cancer. "We will assess the utility of measuring TSLP to inform prognosis and how this might indicate whether more specific treatment plans may be necessary in some cases," said Dr. Ziegler. His team also will be studying the protein versican that has been shown to turn on TSLP in tumor metastasis. Thomas Wight, PhD, BRI Director of the Matrix Biology Program, and a leading researcher of versican, will be a collaborator on the grant along with Scott Adams, PhD, Professor of Oncology, Department of Immunology at Roswell Park Cancer Institute. Emma Kuan, PhD, a postdoctoral fellow in Dr. Ziegler's laboratory, is a major contributor and researcher on the grant.


'/>"/>

Contact: Kay Branz
kbranz@benaroyaresearch.org
206-342-6903
Immune Tolerance Network
Source:Eurekalert

Related medicine news :

1. Benaroya Research Institute announces $4.4 million grant for type 1 diabetes
2. Benaroya Research Institute receives 7-year award to lead Immune Tolerance Network
3. UCLA Brain Injury Research Center gets NCAA funding for research on sports concussions
4. NIH awards $20 million over 5 years to train next generation of global health researchers
5. Researchers develop a new cell and animal model of inflammatory breast cancer
6. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
7. Sexually abused boys at risk for more unsafe sex: UBC research
8. Researchers Find Gene Mutations That May Be a Key to Autism
9. LSUHSC research finds HPV-related head & neck cancers rising, highest in middle-aged white men
10. Researchers find evidence of banned antibiotics in poultry products
11. Presidential keynote address and new research highlights from the American Society of Pediatric Otolaryngology meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... 24, 2017 , ... “The Adventures of Joey, The Dog Who Barks at ... his life to the fullest, as God intended. “The Adventures of Joey, The Dog ... and grandmother pursuing her passion for writing, especially about truth and human behavior. , ...
(Date:3/23/2017)... ... March 23, 2017 , ... A recent report from the National Council ... programs. The NCTQ report suggests, based on a review of GPA and SAT/ACT requirements ... quality in the U.S. It argues that this higher bar should be set by ...
(Date:3/23/2017)... ... 2017 , ... Demonstrating their commitment to improving health and ... have been awarded national accreditation through the Public Health Accreditation Board ... of communities across the nation whose health departments meet rigorous national standards for ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Center at 10 North Broadway Avenue, will be an educational and exciting program ... instruction in the management of chronic pain. , Oklahoma is in a healthcare ...
(Date:3/23/2017)... and Grimsby, Ontario (PRWEB) , ... March 23, 2017 , ... The MBI “Hall of ... industry or whose acts have had a significant impact on the careers of all others ... Marketing with NRB Inc. was inducted into the MBI’s Hall of Fame. The induction ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... , March 24, 2017  Zymo ... company, and Hamilton Robotics, Inc., who designs, ... an ongoing collaboration that teams Zymo Research,s ... RNA and DNA extraction products with Hamilton,s ... created optimized methods for microbiomics and RNA ...
(Date:3/24/2017)... 24, 2017 ShangPharma, a leading ... cost-effective drug development and discovery services, technology, ... industry, announced today the intent for a ... be consolidating the Contract Research Organizations (CRO) ... ChemPartner. These entities include ChemPartner Shanghai, ChemPartner ...
(Date:3/24/2017)... 24, 2017 A ReportsnReports.com report says, over ... rapidly as the global sales of Adcetris and Kadcyla have been ... antibody drug conjugates market is driven by large number of ADC ... therapeutic window offered by ADCs. ... Browse 3 Tables and 94 Figures, 10 Major Company ...
Breaking Medicine Technology: